Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials

被引：0
作者：
R Iacovelli
A Altavilla
G Procopio
S Bracarda
M Santoni
S Cascinu
E Cortesi
机构：
[1] Oncology and Human Pathology,Department of Radiology
[2] Oncology Unit B,Department of Medical Oncology
[3] Sapienza University of Rome,undefined
[4] Fondazione IRCCS Istituto Nazionale dei Tumori,undefined
[5] Medical Oncology Unit 1,undefined
[6] Azienda Sanitaria USL 8,undefined
[7] Medical Oncology Unit,undefined
[8] Polytechnic University of the Marche Region,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2013年 / 16卷
关键词：
castration-resistant prostate cancer; second line; abiraterone acetate; cabazitaxel; enzalutamide; performance status;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：323 / 327
页数：4
相关论文
共 50 条
  • [21] Neutrophil-lymphocyte ratio is a predictor of prognosis in patients with castration-resistant prostate cancer: a meta-analysis
    Wang, Zhun
    Peng, Shuanghe
    Xie, Hui
    Guo, Linpei
    Jiang, Ning
    Shang, Zhiqun
    Niu, Yuanjie
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 3599 - 3610
  • [22] Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate
    Yamamoto, Akiyuki
    Kato, Masashi
    Matsui, Hirotaka
    Ishida, Ryo
    Kimura, Tohru
    Funahashi, Yasuhito
    Sassa, Naoto
    Matsukawa, Yoshihisa
    Kamihira, Osamu
    Hattori, Ryohei
    Gotoh, Momokazu
    Tsuzuki, Toyonori
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (03) : 584 - 590
  • [23] Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer
    Higano, Celestia S.
    Beer, Tomasz M.
    Taplin, Mary-Ellen
    Efstathiou, Eleni
    Hirmand, Mohammad
    Forer, David
    Scher, Howard I.
    EUROPEAN UROLOGY, 2015, 68 (05) : 795 - 801
  • [24] Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate
    Akiyuki Yamamoto
    Masashi Kato
    Hirotaka Matsui
    Ryo Ishida
    Tohru Kimura
    Yasuhito Funahashi
    Naoto Sassa
    Yoshihisa Matsukawa
    Osamu Kamihira
    Ryohei Hattori
    Momokazu Gotoh
    Toyonori Tsuzuki
    International Journal of Clinical Oncology, 2018, 23 : 584 - 590
  • [25] Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis
    Miura, Noriyoshi
    Mori, Keiichiro
    Mostafaei, Hadi
    Quhal, Fahad
    Motlagh, Reza Sari
    Abufaraj, Mohammad
    Pradere, Benjamin
    Aydh, Abdulmajeed
    Laukhtina, Ekaterina
    D'Andrea, David
    Saika, Takashi
    Shariat, Shahrokh F.
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (11) : 1881 - 1891
  • [26] Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study
    Omrcen, Tomislav
    Eterovic, Davor
    Vrdoljak, Eduard
    ANTI-CANCER DRUGS, 2020, 31 (07) : 742 - 746
  • [27] Longitudinal model–based meta-analysis for survival probabilities in patients with castration-resistant prostate cancer
    Wenjun Chen
    Liang Li
    Shuangmin Ji
    Xuyang Song
    Wei Lu
    Tianyan Zhou
    European Journal of Clinical Pharmacology, 2020, 76 : 589 - 601
  • [28] The efficacy and safety of zibotentan in the treatment of castration-resistant prostate cancer: a meta-analysis
    Wu, Y.
    Shao, N.
    Shen, Z. -X.
    Li, Q.
    Wang, Y.
    Li, C.
    Ma, G.
    Dong, J.
    Lu, X. -J.
    Feng, N. -H.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2014, 18 (21) : 3291 - 3296
  • [29] Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis
    Roumiguie, Mathieu
    Paoletti, Xavier
    Neuzillet, Yann
    Mathieu, Romain
    Vincendeau, Sebastien
    Kleinclauss, Francois
    Mejean, Arnaud
    Guy, Laurent
    Timsit, Marc Olivier
    Lebret, Thierry
    FUTURE ONCOLOGY, 2021, 17 (14) : 1811 - 1823
  • [30] No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer
    Miyake, Hideaki
    Sugiyama, Takayuki
    Aki, Ryota
    Matsushita, Yuto
    Tamura, Keita
    Motoyama, Daisuke
    Ito, Toshiki
    Otsuka, Atsushi
    MEDICAL ONCOLOGY, 2017, 34 (08)
12345